TY - JOUR
T1 - The impact of Rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation
T2 - A real-world study
AU - Wei, Xiya
AU - Xie, Yiyu
AU - Jiang, Ruoyu
AU - Li, Huiyu
AU - Wu, Heqing
AU - Zhang, Yuqi
AU - Li, Ling
AU - Zhou, Shiyuan
AU - Ma, Xiao
AU - Tang, Zaixiang
AU - He, Jun
AU - Wu, Depei
AU - Wu, Xiaojin
N1 - Publisher Copyright:
Copyright © 2022 Wei, Xie, Jiang, Li, Wu, Zhang, Li, Zhou, Ma, Tang, He, Wu and Wu.
PY - 2022/8/31
Y1 - 2022/8/31
N2 - Rituximab is used to eliminate B cells as a chimeric monoclonal antibody directed against CD20, a B-cell antigen expressed on B cells. To explore the impact of rituximab administered before transplantation, we implemented a retrospective, monocentric study and utilized real-world data collected at our center between January 2018 and December 2020, and then followed until December 2021. Based on whether a dose of 375mg/m2 rituximab was used at least once within two weeks before transplantation, patients undergoing allo-HSCT were classified into two groups: rituximab (N=176) and non-rituximab (N=344) group. Amongst all the patients, the application of rituximab decreased EBV reactivation (P<0.01) and rituximab was an independent factor in the prevention of EBV reactivation by both univariate and multivariate analyses (HR 0.56, 95%CI 0.33-0.97, P=0.04). In AML patients, there were significant differences in the cumulative incidence of aGVHD between the two groups (P=0.04). Our data showed that rituximab was association with a decreased incidence of aGVHD in AML patients according to both univariate and multivariate analyses. There was no difference between the two groups in other sets of populations. Thus, our study indicated that rituximab administered before transplantation may help prevent EBV reactivation in all allo-HSCT patients, as well as prevent aGVHD in AML patients after allo-HSCT.
AB - Rituximab is used to eliminate B cells as a chimeric monoclonal antibody directed against CD20, a B-cell antigen expressed on B cells. To explore the impact of rituximab administered before transplantation, we implemented a retrospective, monocentric study and utilized real-world data collected at our center between January 2018 and December 2020, and then followed until December 2021. Based on whether a dose of 375mg/m2 rituximab was used at least once within two weeks before transplantation, patients undergoing allo-HSCT were classified into two groups: rituximab (N=176) and non-rituximab (N=344) group. Amongst all the patients, the application of rituximab decreased EBV reactivation (P<0.01) and rituximab was an independent factor in the prevention of EBV reactivation by both univariate and multivariate analyses (HR 0.56, 95%CI 0.33-0.97, P=0.04). In AML patients, there were significant differences in the cumulative incidence of aGVHD between the two groups (P=0.04). Our data showed that rituximab was association with a decreased incidence of aGVHD in AML patients according to both univariate and multivariate analyses. There was no difference between the two groups in other sets of populations. Thus, our study indicated that rituximab administered before transplantation may help prevent EBV reactivation in all allo-HSCT patients, as well as prevent aGVHD in AML patients after allo-HSCT.
KW - aGVHD: acute graft vs host disease
KW - allogeneic hematopoietic stem cell transplantation
KW - B cell
KW - EBV - Epstein-Barr virus
KW - prior to transplantation
KW - rituximab
UR - http://www.scopus.com/inward/record.url?scp=85138131155&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2022.967026
DO - 10.3389/fimmu.2022.967026
M3 - Article
C2 - 36119024
AN - SCOPUS:85138131155
SN - 1664-3224
VL - 13
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 967026
ER -